Two-Item Conjoint Screen (TICS) for Alcohol and Other Drug Problems
Share
In the past 12 months:
1. Have you ever drunk or used drugs more than you meant to?
2. Have you felt you wanted or needed to cut down on your drinking or drug use?
0 positive responses
Interpretation:
- If the patient answers no to both questions, it is considered a negative screening result; the patient is unlikely to have a current alcohol or drug problem.
- If the patient answers yes to one or both questions, it is considered a positive screening result and may suggest a current alcohol or drug problem; the patient should have more detailed diagnostic assessments for an alcohol or drug problem. A positive response to at least one question detects a current substance use disorder with a sensitivity of 79.3% and specificity of 77.9%.
Performance in Primary Care Patients
In this study, investigators recruited 1,252 primary care patients aged 18 to 59 and among the 1,136 patients that participated in the study, there was a 23.0% prevalence of a substance use disorder.
| Positive Responses | Positive Predictive Value | Likelihood Ratios |
|---|---|---|
| 0 | 7.3% | 0.27 |
| 1 | 36.5% | 1.93 |
| 2 | 72.4% | 8.77 |
Source
- Brown RL, Leonard T, Saunders LA, Papasouliotis O. A two-item conjoint screen for alcohol and other drug problems. J Am Board Fam Pract. 2001;14:95-106.
This calculator operates entirely from your device.
No input variables or data is transmitted between your computer and our servers.
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant